{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:21:53Z","timestamp":1788376913662,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Poly (ADP-ribose) polymerase inhibitors have been increasingly used in ovarian cancer treatment. However, the real-world safety data of these drugs in Japanese patients are limited. This retrospective study included 181 patients with ovarian cancer who received olaparib or niraparib at two independent hospitals in Japan between May 2018 and December 2022. Clinical information and blood sampling data were collected. Regarding patient backgrounds, the olaparib group had higher proportions of patients with serous carcinoma,\n                    <jats:italic>BRCA<\/jats:italic>\n                    positivity, homologous recombination deficiency, and those receiving maintenance therapy after recurrence treatment than the niraparib group. Regarding toxicity properties, the most common reasons for discontinuation in the olaparib group were anemia, fatigue, and nausea, while the reason in the niraparib was thrombocytopenia. Thrombocytopenia caused by niraparib treatment occurred earlier than anemia caused by olaparib treatment. Patients with a low body mass index or who had undergone several previous treatment regimens were more likely to discontinue treatment within the first 3\u00a0months. Although we analyzed blood collection data, predicting treatment interruptions due to blood toxicity was challenging. In this study, we revealed the characteristics of patients and the timing of interruptions for each drug, highlighting the importance of carefully managing adverse effects.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-63600-z","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:02:50Z","timestamp":1717207370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Ryosuke","family":"Uekusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"63600_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"63600_CR2","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata, S. et al. Treatment of recurrent ovarian cancer. Ann. Oncol. 28, viii51\u2013viii56. https:\/\/doi.org\/10.1093\/annonc\/mdx441 (2017).","journal-title":"Ann. Oncol."},{"key":"63600_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim, A., Ueda, Y., Naka, T. & Enomoto, T. Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res. 31, 14. https:\/\/doi.org\/10.1186\/1756-9966-31-14 (2012).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"63600_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"63600_CR5","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708816","author":"MJ Schiewer","year":"2018","unstructured":"Schiewer, M. J. et al. PARP-1 regulates DNA repair factor availability. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201708816 (2018).","journal-title":"EMBO Mol. Med."},{"key":"63600_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084203","author":"G Valabrega","year":"2021","unstructured":"Valabrega, G., Scotto, G., Tuninetti, V., Pani, A. & Scaglione, F. Differences in PARP inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy. Int J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22084203 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"63600_CR7","doi-asserted-by":"publisher","first-page":"e390876","DOI":"10.1200\/EDBK_390876","volume":"43","author":"M Friedlander","year":"2023","unstructured":"Friedlander, M., Lee, Y. C. & Tew, W. P. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: A synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book 43, e390876. https:\/\/doi.org\/10.1200\/EDBK_390876 (2023).","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"63600_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","volume":"29","author":"JS Berek","year":"2018","unstructured":"Berek, J. S. et al. Safety and dose modification for patients receiving niraparib. Ann. Oncol. 29, 1784\u20131792. https:\/\/doi.org\/10.1093\/annonc\/mdy181 (2018).","journal-title":"Ann. Oncol."},{"key":"63600_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.21873\/anticanres.16231","volume":"43","author":"C Shiraishi","year":"2023","unstructured":"Shiraishi, C., Hirai, T., Ogura, T. & Iwamoto, T. Analysis of clinical factors in olaparib-related anemia using adverse drug event reporting databases. Anticancer Res. 43, 883\u2013891. https:\/\/doi.org\/10.21873\/anticanres.16231 (2023).","journal-title":"Anticancer Res."},{"key":"63600_CR10","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535 (2012).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2 (2017).","journal-title":"Lancet Oncol."},{"key":"63600_CR12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858 (2018).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361 (2019).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR14","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310 (2016).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962 (2019).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore, K. N. et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 636\u2013648. https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4 (2019).","journal-title":"Lancet Oncol."},{"key":"63600_CR17","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman, R. E. et al. Real-world evidence - What is it and what can it tell us?. N. Engl. J. Med. 375, 2293\u20132297. https:\/\/doi.org\/10.1056\/NEJMsb1609216 (2016).","journal-title":"N. Engl. J. Med."},{"key":"63600_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth, C. M., Karim, S. & Mackillop, W. J. Real-world data: Towards achieving the achievable in cancer care. Nat. Rev. Clin. Oncol. 16, 312\u2013325. https:\/\/doi.org\/10.1038\/s41571-019-0167-7 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63600_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-20-1064","volume":"20","author":"H Zheng","year":"2021","unstructured":"Zheng, H. et al. Real-world experience of olaparib treatment in patients with ovarian cancer: A Chinese multicenter study. Mol. Cancer Ther. 20, 1735\u20131742. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-1064 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"63600_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13048-021-00803-2","volume":"14","author":"J Ni","year":"2021","unstructured":"Ni, J. et al. The efficacy and safety of niraparib for ovarian cancer: A single-center observational study from China. J. Ovarian Res. 14, 68. https:\/\/doi.org\/10.1186\/s13048-021-00803-2 (2021).","journal-title":"J. Ovarian Res."},{"key":"63600_CR21","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.2217\/fon-2019-0471","volume":"15","author":"JR Gallagher","year":"2019","unstructured":"Gallagher, J. R. et al. Real-world adverse events with niraparib 200 mg\/day maintenance therapy in ovarian cancer: A retrospective study. Future Oncol. 15, 4197\u20134206. https:\/\/doi.org\/10.2217\/fon-2019-0471 (2019).","journal-title":"Future Oncol."},{"key":"63600_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2022.12.023","volume":"182","author":"JF Cueva","year":"2023","unstructured":"Cueva, J. F. et al. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. Eur. J. Cancer 182, 3\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.023 (2023).","journal-title":"Eur. J. Cancer"},{"key":"63600_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","volume":"18","author":"M Zhao","year":"2023","unstructured":"Zhao, M. et al. Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multicenter study in China. Target Oncol. 18, 869\u2013883. https:\/\/doi.org\/10.1007\/s11523-023-00999-x (2023).","journal-title":"Target Oncol."},{"key":"63600_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","volume":"163","author":"N Colombo","year":"2021","unstructured":"Colombo, N. et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol. Oncol. 163, 41\u201349. https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.016 (2021).","journal-title":"Gynecol. Oncol."},{"key":"63600_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","volume":"143","author":"I Tsibulak","year":"2019","unstructured":"Tsibulak, I., Zeimet, A. G. & Marth, C. Hopes and failures in front-line ovarian cancer therapy. Crit. Rev. Oncol. Hematol. 143, 14\u201319. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.08.002 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"63600_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615. https:\/\/doi.org\/10.1038\/nature10166 (2011).","journal-title":"Nature"},{"key":"63600_CR27","doi-asserted-by":"publisher","first-page":"102040","DOI":"10.1016\/j.ctrv.2020.102040","volume":"87","author":"I Ruscito","year":"2020","unstructured":"Ruscito, I. et al. Incorporating parp-inhibitors in primary and recurrent ovarian cancer: A meta-analysis of 12 phase II\/III randomized controlled trials. Cancer Treat Rev. 87, 102040. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102040 (2020).","journal-title":"Cancer Treat Rev."},{"key":"63600_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ygyno.2020.07.020","volume":"159","author":"CM Eakin","year":"2020","unstructured":"Eakin, C. M., Ewongwo, A., Pendleton, L., Monk, B. J. & Chase, D. M. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecol. Oncol. 159, 112\u2013117. https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.020 (2020).","journal-title":"Gynecol. Oncol."},{"key":"63600_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jncimonographs\/lgad010","volume":"2023","author":"SA Purcell","year":"2023","unstructured":"Purcell, S. A. et al. Pharmacokinetics of cancer therapeutics and energy balance: The role of diet intake, energy expenditure, and body composition. J. Natl. Cancer Inst. Monogr. 2023, 3\u201311. https:\/\/doi.org\/10.1093\/jncimonographs\/lgad010 (2023).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"63600_CR30","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1200\/JCO.19.00917","volume":"37","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent Ovarian cancer: A TWiST analysis of the ENGOT-OV16\/NOVA trial. J Clin Oncol 37, 3183\u20133191. https:\/\/doi.org\/10.1200\/JCO.19.00917 (2019).","journal-title":"J Clin Oncol"},{"key":"63600_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu, X. H. et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial(\u2606). Ann. Oncol. 32, 512\u2013521. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.018 (2021).","journal-title":"Ann. Oncol."},{"key":"63600_CR32","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue, C. J., Dal Molin, G. Z., Sood, A. K. & Coleman, R. L. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 20, e15\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1 (2019).","journal-title":"Lancet Oncol."},{"key":"63600_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103026","author":"A Stemmer","year":"2020","unstructured":"Stemmer, A., Shafran, I., Stemmer, S. M. & Tsoref, D. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for platinum-sensitive ovarian cancer: Systematic review and network meta-analysis. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12103026 (2020).","journal-title":"Cancers (Basel)"},{"key":"63600_CR34","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"PM Morice","year":"2021","unstructured":"Morice, P. M. et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: A safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 8, e122\u2013e134. https:\/\/doi.org\/10.1016\/S2352-3026(20)30360-4 (2021).","journal-title":"Lancet Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63600-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:03:33Z","timestamp":1717207413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63600-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["63600"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-63600-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12595"}}